首页 | 本学科首页   官方微博 | 高级检索  
     

扶正解毒方联合吉西他滨和顺铂对晚期非小细胞肺癌患者T细胞亚群和血清肿瘤标志物的影响
引用本文:王伟,金朝晖,范伏元,赵四林,李妲,符艳,孙爽,肖雪飞,张慧卿,闵锐. 扶正解毒方联合吉西他滨和顺铂对晚期非小细胞肺癌患者T细胞亚群和血清肿瘤标志物的影响[J]. 现代生物医学进展, 2021, 0(4): 710-713
作者姓名:王伟  金朝晖  范伏元  赵四林  李妲  符艳  孙爽  肖雪飞  张慧卿  闵锐
作者单位:湖南中医药大学第一附属医院呼吸内科 湖南 长沙 410007
基金项目:湖南省中医药科研计划项目(201838)
摘    要:目的:探讨扶正解毒方联合吉西他滨和顺铂对晚期非小细胞肺癌(NSCLC)患者T细胞亚群和血清肿瘤标志物的影响.方法:选取2017年3月~2018年12月期间我院接受的晚期NSCLC患者80例,根据随机数字法将患者分为对照组(n=40,给予吉西他滨和顺铂治疗)和研究组(n=40,给予扶正解毒方联合吉西他滨和顺铂治疗).比较...

关 键 词:扶正解毒方  吉西他滨  顺铂  晚期  非小细胞肺癌  T细胞亚群  肿瘤标志物
收稿时间:2020-06-26
修稿时间:2020-07-22

Effect of Fuzheng Jiedu Formula Combined with Gemcitabine and Cisplatin on T Cell Subsets and Serum Tumor Markers in Patients with Advanced Non-small Cell Lung Cancer
WANG Wei,JIN Zhao-hui,FAN Fu-yuan,ZHAO Si-lin,LI Da,FU Yan,SUN Shuang,XIAO Xue-fei,ZHANG Hui-qing,MIN Rui. Effect of Fuzheng Jiedu Formula Combined with Gemcitabine and Cisplatin on T Cell Subsets and Serum Tumor Markers in Patients with Advanced Non-small Cell Lung Cancer[J]. Progress in Modern Biomedicine, 2021, 0(4): 710-713
Authors:WANG Wei  JIN Zhao-hui  FAN Fu-yuan  ZHAO Si-lin  LI Da  FU Yan  SUN Shuang  XIAO Xue-fei  ZHANG Hui-qing  MIN Rui
Affiliation:(Department of Respiratory Medicine,The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine,Changsha,Hunan,4J0007,China)
Abstract:ABSTRACT Objective: To investigate the effect of Fuzheng Jiedu formula combined with gemcitabine and cisplatin on T cell subsets and serum tumor markers in patients with advanced non-small cell lung cancer (NSCLC). Methods: 80 patients with advanced NSCLC who were admitted to our hospital from March 2017 to December 2018 were selected, patients were divided into control group (n=40, treatmented with gemcitabine and cisplatin) and study group (n=40, treatmented with Fuzheng Jiedu Fang combined with gemcitabine and cisplatin) according to the random number method. The therapeutic effect, T cell subsets and serum tumor markers were compared between the two groups, and the adverse reactions of two groups were recorded. Results: The total clinical effective rate of the study group at 4 cycles after treatment was higher than that of the control group (P<0.05). CD3+, CD4+, CD4+/CD8+ in the two groups at 4 cycles after treatment decreased compared with those before treatment, but the study group was higher than the control group (P<0.05). CD8+ in the two groups at 4 cycles after treatment increased compared with that before treatment, but the study group was lower than the control group (P<0.05). The levels of carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125) and carbohydrate antigen 199 (CA199) of the two groups at 4 cycles after treatment were lower than those before treatment, the study group was lower than the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Fuzheng Jiedu formula combined with gemcitabine and cisplatin in the treatment of advanced NSCLCpatients, the effect is good, which can effectively prevent the progress of disease, reduce the immunosuppression, and has a good safety, and which has a certain clinical application value.
Keywords:Fuzheng Jiedu formula   Gemcitabine   Cisplatin   Advanced   Non-small cell lung cancer   T cell subsets   Tumor markers
本文献已被 维普 等数据库收录!
点击此处可从《现代生物医学进展》浏览原始摘要信息
点击此处可从《现代生物医学进展》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号